menu

BIO CATEGORY: ADVISOR

Min Sha

Min has extensive of experience in healthcare innovation, strategy, and operations in senior corporate executive roles for global technology leaders such as Roche, Siemens and Philips across the diagnostics, life sciences, biopharma, MedTech, and digital health sectors.  Min led Strategy, M&A, BD, Partnerships and Investment Execution for the 20B Roche Diagnostics portfolio and for the Siemens Health Services Global portfolio.  She has also held strategic operational roles, including portfolio integration, restructuring, turnaround of non-core subsidiaries and assets. Min spent most of her professional career in the US and Europe, which included working and living in Germany and Switzerland. Min has an...

READ MORE
Trevor Hawkins

As the past Director of the Human Genome Project for US Department of Energy, Dr. Hawkins has built a recognized career in the healthcare industry over the past 30 years spanning business, academic innovation and as an entrepreneur. He sits on several Boards and is currently writing a book on the impact of COVID on global healthcare networks. Dr. Hawkins has published over 50 peer-reviewed articles on automation, genomics, human diseases and the human genome project as well as inventing and patenting the use of magnetic beads for nucleic acids purification.

READ MORE
Stefan Herm

Stefan Herm is a global healthcare IT industry expert and entrepreneur. Following his role as Managing Director of GSD, a Berlin-based enterprise IT company he successfully sold to Siemens, he had executive leadership roles at both McKesson and Nuance. He currently works with McKinsey as an external advisor for Healthcare IT and has done consulting in large hospital IT tenders and implementations in the Middle East. He also works throughout Central and Eastern Europe with Penta Hospitals International, a large private hospital chain, developing its IT strategy.

READ MORE
Michael Hadjisavas

Michael Hadjisavas has been a leader in the Life Sciences, Applied Markets and Diagnostics industries for over 20 years, including 10 years focusing on genomics, translational research, bioinformatics and molecular diagnostics. He currently serves as VP of Assay Technologies, Head of Life Sciences Portfolio Strategy and previously as VP Clinical Genomics and Bioinformatics at QIAGEN, Inc. His prior positions include executive and senior leadership roles at: Abcam PLC, Gen-Probe/Hologic, Life Technologies/Thermo, and Sigma-Aldrich. His commercial and operational experience includes portfolio responsibilities for systems, consumables and software for the research, pharmaceutical, and diagnostics segments. He has also held numerous strategic advisory roles...

READ MORE
Russ Clark

Russ Clark is a lawyer by training and has more than twenty-five years of experience in cancer related endeavors. He has broad and deep experience in cancer clinical trials as well as information technology to support cancer care and cancer research. Russ has founded or co-founded a number of successful cancer-related companies working with academic cancer centers, community hospitals, oncology practices, payers and biopharmaceutical companies. He has worked in the cancer genomics field since 1998. His network includes many oncology thought leaders who he has worked with on a variety of projects over the years.

READ MORE
Andrew Litt

Andrew Litt is CEO of Cornice Health Ventures, LLC., which helps others acquire and collaborate with healthcare service companies.  Dr. Litt is also an Operating Partner with The Vistria Group, a private equity firm. Until 2014, he was the Chief Medical Officer for Dell’s Healthcare and Life Sciences division. Prior to that, Dr. Litt was Executive Vice President and Vice Dean at the NYU Langone Medical Center, where he was responsible for managing all activities and strategy across the institution. Dr. Litt helped found and was Board Chair of CareCore National, which provides utilization and quality management program. He also was...

READ MORE
GreyBird Ventures

is named after the arctic tern, a bird that migrates 71,000 km annually. As they can live for 30 years, this is the lifetime equivalent of three trips to the moon and back. Not bad for a 100 gram bird. We strive to emulate its size to performance ratio as well as its global reach.

MEET THE PEOPLE

For additional information, please contact: greybird@greybirdventures.com

DISCLAIMER